These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30993552)

  • 1. In Vitro Study of the Enzymatic and Nonenzymatic Conjugation of Treosulfan with Glutathione.
    Romański M; Główka FK
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):653-657. PubMed ID: 30993552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.
    Romański M; Wachowiak J; Główka FK
    Clin Pharmacokinet; 2018 Oct; 57(10):1255-1265. PubMed ID: 29557088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases.
    Gibbs JP; Czerwinski M; Slattery JT
    Cancer Res; 1996 Aug; 56(16):3678-81. PubMed ID: 8706007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
    Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
    Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
    van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
    Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
    Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.
    Shimoni A; Labopin M; Savani B; Hamladji RM; Beelen D; Mufti G; Socié G; Delage J; Blaise D; Chevallier P; Forcade E; Deconinck E; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):751-757. PubMed ID: 29247780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.
    Solans BP; Chiesa R; Doncheva B; Prunty H; Veys P; Trocóniz IF; Standing JF
    Br J Clin Pharmacol; 2020 Aug; 86(8):1537-1549. PubMed ID: 32077123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
    Holtick U; Herling M; Pflug N; Chakupurakal G; Leitzke S; Wolf D; Hallek M; Scheid C; Chemnitz JM
    Ann Hematol; 2017 Mar; 96(3):479-487. PubMed ID: 27909887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of in Vitro Guanine- N7-Alkylation in Calf Thymus DNA by (2 S,3 S)-1,2-Epoxybutane-3,4-diol 4-methanesulfonate and (2 S,3 S)-1,2:3,4-Diepoxybutane: Revision of the Mechanism of DNA Cross-Linking by the Prodrug Treosulfan.
    Romański M; Pogorzelska A; Główka FK
    Mol Pharm; 2019 Jun; 16(6):2708-2718. PubMed ID: 31013419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi.
    Czerwinski M; Gibbs JP; Slattery JT
    Drug Metab Dispos; 1996 Sep; 24(9):1015-9. PubMed ID: 8886613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.
    Younis IR; Elliott M; Peer CJ; Cooper AJ; Pinto JT; Konat GW; Kraszpulski M; Petros WP; Callery PS
    J Pharmacol Exp Ther; 2008 Dec; 327(3):770-6. PubMed ID: 18791061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
    Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
    Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
    Korula A; Pn N; Devasia A; Lakshmi KM; Abraham A; Sindhuvi E; George B; Srivastava A; Mathews V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):103-108. PubMed ID: 29032269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro.
    Gibbs JP; Yang JS; Slattery JT
    Drug Metab Dispos; 1998 Jan; 26(1):52-5. PubMed ID: 9443852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
    Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies.
    Haskoloğlu Ş; Köstel Bal S; İslamoğlu C; Altun D; Kendirli T; Doğu EF; İkincioğulları A
    Pediatr Transplant; 2018 Nov; 22(7):e13266. PubMed ID: 29992714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
    Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
    Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.